CAR-T treated with the demethylating agent decitabine have enhanced proliferation and anti-tumor function, which was associated with altered methylation at key loci, including TCF7, IL-7R, BCL6, and EOMES [68]. This evidence concerns the gene TCF7 and neoplasm.